Anti-diabetic drug market has been potentially growing in India. As several drugs have been launched by various Indian pharmaceutical companies, Zydus Cadila has made a breakthrough in the diabetes drug market by launching its new drug at the most affordable cost.
Cadila has offered its drug Tenglyn, the generic version of oral anti-diabetic drug gliptins at a price of Rs. 7 per tablet in India. Gliptins have been ruling the diabetes market with its potential to induce insulin in the blood. Several pharma companies like Glenmark, Ajanta are already selling the same drug at a cost of Rs. 20 per tablet.
New Inexpensive Cancer Drug Launched by Cadila
Cadila Pharmaceuticals has just announced the entry of its new drug for lung cancer management. This is seen as an important development in the treatment of lung cancer.
Advertisement
‘The new anti-diabetic drug, Tenglyn offered at a price of rs.7 per tablet will be a boon for 60 million diabetic patients in India.’
Tweet it Now
"With Tenglyn we provide patients suffering from diabetes access to this advanced treatment at the most affordable cost," said Sharvil Patel, Deputy Managing Director, Zydus Cadila.
Therefore, this new launch of the same drug at a cost of rs.7 will help 60 million diabetic patients economically. The cost-effective drug will also be made easily accessible all over the country. The price of Zydus is said to be one sixth of all other pharmaceutical companies.
Source: Medindia
Source: Medindia
The US Regulatory Authorities Approve Novo's New Diabetes Drug 'Tresiba'
The US Food and Drug Administration's approval was based on the clinical trials that showed the drug, Tresiba can improve glycemic control.
Advertisement
 Glenmark India Launches Teneligliptin for Management of Type 2 DiabetesTeneligliptin is an advanced new third-generation oral anti-diabetic agent that suppresses' glucagon release and increases insulin to lower blood glucose levels. | Advertisement
|
USFDA Halts the Launch of AstraZeneca’s Fixed-Dose Diabetes Drug for Treatment
US heath regulators stated that more clinical data were required before it could approve the combination of saxagliptin and dapagliflozin for diabetes treatment.
Advertisement
Recommended Reading
Latest Diabetes News
Type 2 diabetes mice injected with beta cells with increased CD63 protein marker production had their blood sugar levels restored to normal.
Good news to children with diabetes: New artificial pancreas can help improve blood sugar control in kids.
New study reveals the link between pre-sleep light exposure and gestational diabetes mellitus in pregnant women.
Spinal cord stimulation delivers electrical stimulation to the spinal cord to cut off pain signals to the brain and may ease pain associated with diabetic neuropathy.
Cognitive behavioral therapy delivered via smartphone app was found to lower blood sugar levels in type 2 diabetes people.